ERBB2 and neoplasm: The combination of two HER-2 targeted therapies produced tumor regression in the models.19,192 In gastrointestinal stromal tumors (GIST), tyrosine-protein kinase KIT has been a key target, while secondary KIT mutation is the central drug-resistance mechanism against tyrosine kinase inhibitors (TKI).